BALZIVA-28 Drug Patent Profile
✉ Email this page to a colleague
When do Balziva-28 patents expire, and when can generic versions of Balziva-28 launch?
Balziva-28 is a drug marketed by Barr and is included in one NDA.
The generic ingredient in BALZIVA-28 is ethinyl estradiol; norethindrone. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BALZIVA-28?
- What are the global sales for BALZIVA-28?
- What is Average Wholesale Price for BALZIVA-28?
Summary for BALZIVA-28
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Patent Applications: | 219 |
| DailyMed Link: | BALZIVA-28 at DailyMed |
US Patents and Regulatory Information for BALZIVA-28
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | BALZIVA-28 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 076238-001 | Apr 22, 2004 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
